Summary & Overview
HCPCS Q9985: Hydroxyprogesterone Caproate Injection, 10 mg
HCPCS Level II code Q9985 represents a 10 mg unit of hydroxyprogesterone caproate delivered by injection. Hydroxyprogesterone caproate is a progestin formulation used in obstetric practice—most notably for prevention of recurrent spontaneous preterm birth in appropriate patients—and the code captures the drug product rather than administration alone. Nationally, precise coding of injectable therapeutics affects drug utilization tracking, payer coverage determinations, and facility billing for outpatient obstetric services.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of clinical context for the product, typical sites of service where the drug is administered, and the role HCPCS coding plays in billing and reimbursement workflows. The publication outlines benchmarks and policy considerations relevant to payers and providers, including how drug-level HCPCS codes are used for claim adjudication and inventory management. Where payer-specific policy details are unavailable in the source input, the report notes that data is not available and focuses on universally applicable coding and clinical implications. The summary serves clinicians, billing professionals, and policy analysts seeking a concise reference on HCPCS Level II code Q9985 and its place in outpatient obstetric medication billing.
Billing Code Overview
HCPCS Level II code Q9985 describes an injection of hydroxyprogesterone caproate, not otherwise specified, 10 mg. This code represents administration of a progestin formulation commonly used in obstetric care for prevention of recurrent preterm birth in eligible patients.
Service type: injectable medication administration.
Typical site of service: outpatient clinic, ambulatory care setting, or hospital outpatient department, where injectable obstetric therapies are administered.
Data not available in the input for modifiers, associated taxonomies, ICD-10 diagnoses, related codes, and service line.
Clinical & Coding Specifications
Clinical Context
A typical patient is a pregnant adult with a history of a prior spontaneous preterm birth now presenting for preventive therapy. At a routine obstetric visit between 16 and 24 weeks gestation, the obstetric provider documents the prior spontaneous preterm delivery and discusses risk-reduction options. The patient consents to weekly intramuscular injections of hydroxyprogesterone caproate. The clinical workflow includes verification of gestational age and maternal eligibility, medication preparation and dose verification (each vial contains 10 mg increments per Q9985 billing unit), administration of Q9985 via intramuscular injection (usually gluteal), observation for immediate adverse reactions, documentation of lot number and injection site, and scheduling of subsequent weekly injections through approximately 36 weeks gestation or until delivery. Typical sites of service are outpatient obstetrics clinics, maternal-fetal medicine clinics, freestanding ambulatory injection centers, and hospital outpatient departments providing prenatal care.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure | Use when a distinct E/M visit is provided the same day as and documented as separate from the injection encounter |